Efferon raises €4.3M seed round to expand sepsis device sales

What's the deal? Efferon, a Villach, Austria-based maker of hemoadsorption devices, has raised €4.3 million in seed funding from existing private investors in the DACH region. The round brings the company's total raised to €6.8 million.

What's the endgame? Efferon builds devices that remove endotoxins and excessive inflammatory mediators from the bloodstream, targeting critical care settings such as sepsis and septic shock. Its product line includes the Efferon LPSDealroom has a profile for this one. Try Dealroom → and Efferon NEO devices.

Where's the money going? The company plans to expand its product portfolio commercially across Europe, India, and Latin America, grow its distributor network, continue regulatory work, and strengthen its clinical evidence base.

By the numbers: Led by chief executive officer Dima Romashin and chief technology officer Ivan Bessonov, Efferon operates across 46 countries through 21 distributors and has completed more than 30,000 treatments.

What could go wrong? A 2026 ex-vivo study reported weak adsorption performance for Efferon LPS under its test conditions. That underscores how clinical evidence and adoption, not funding, will ultimately determine the company's prospects in a competitive field of established hemoperfusion products.

The signal: The raise fits a broader push to develop extracorporeal treatments for sepsis, where devices aim to pull harmful agents directly from the blood. For Efferon, the question is less about the size of the round than whether it can scale production and prove clinical value.

Read more: finsmes.com

Image credit: emilio labrador